Company intelligence / Profile preview

SINOVAC Foundation

Beijing, Haidian District, China

Ownership: Private
Employees: ~652
Development stage: Other

Overview

CoronaVac demonstrated 66% efficacy against symptomatic COVID-19, 88% against hospitalization, and 90% against ICU admission in Chilean population studies. Real-world data from Brazil showed 95% reduction in deaths and 86% reduction in hospitalizations after 75% population vaccination. Indonesian healthcare worker data showed 94% protection against symptomatic infection.[2]

Therapeutic areas: Infectious Diseases
Modalities: Inactivated virus vaccineLive attenuated vaccinePolysaccharide vaccine
Industry: Pharma

Partnerships

China Centers for Disease Control and Prevention

Beyond the preview

Go deeper on SINOVAC Foundation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SINOVAC Foundation.

Explore the full profile